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NK cells expressing TIM-3 show a marked increase in IFNγ production in response to acute myeloid leukemia (AML)
blast cells that endogenously express Gal-9. Herein, we demonstrate that NK cell-mediated production of IFNγ, induced
by TIM-3/Gal-9 interaction and released in bone marrow microenvironment, is responsible for IDO1 expression in AML
blasts. IDO1-expressing AML blasts consequently down-regulate NK cell degranulation activity, by sustaining leukemia
immune escape. Furthermore, the blocking of TIM-3/Gal-9 interaction strongly down-regulates IFNγ-dependent IDO1
activity. Thus, the inhibition of TIM-3/Gal-9 immune check point, which affects NK cell-dependent IFNγ production and
the consequent IDO1 activation, could usefully integrate current chemotherapeutic approaches.
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The interaction between T-cell immunoglobulin mucin
(TIM)-3 and Galectin-9 (Gal-9) mediates signaling path-
ways involved in infection, autoimmunity, inflammation,
peripheral tolerance, and tumor immunity [1]. TIM-3 is a
type I membrane glycoprotein, highly expressed on mur-
ine and human natural killer (NK) cells [2]. Gal-9 is a
S-type β-galactoside-binding lectin, known as a ligand for
TIM-3, and highly expressed in tissues of immune system
such as lymph nodes, thymus, spleen, and bone marrow
[3]. Recent analyses revealed acute myeloid leukemia
(AML) blast cells to be positive for Gal-9 expression [4].
NK-cell function may play a role in antitumor surveil-
lance that is distinct from MHC-restricted cytolytic activ-
ity of T cells [5]. Recent studies suggest that NK cell-based
immunotherapy may be an effective approach for patients
with leukemia, and emerging strategies based on adoptive
transfer of NK cells are now under investigation [6-8].
Indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme able to
degrade tryptophan into kynurenine, is a nodal mediator
of pathogenic inflammation and immune escape in cancer.
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(Treg). The gene encoding IDO1 was the first interferon
(IFN)-activated gene to be described [9].
In our recent paper by Folgiero et al., we demonstrated
that in 51% of samples obtained from AML pediatric pa-
tients, IDO1 was up-regulated in response to IFNγ and
negatively correlated with prognosis. However, until
now, the microenvironmental source of IFNγ in child-
hood AML remained to be identified [10]. Since NK
cells are the main cell population expressing TIM-3 in
response to cytokine stimulation and as the engagement
of TIM-3 with Gal-9 ligand induces significant increase
in IFNγ production by NK cells [4], we speculated that
TIM-3/Gal-9 interaction in BM could be responsible of
IDO1 induction in AML blasts and could contribute to
mediate the consequent immune escape mechanism.
We evaluated the level of Gal-9 expression in AML blasts
and confirmed that NK cells obtained from peripheral
blood of healthy donors were TIM-3 positive (Additional
file 1: Figure S1A, B). To mimic leukemia-conditioned
microenvironment, NK cells from healthy donors were co-
cultured with AML blasts that did not spontaneously ex-
press IDO1. After 24 h of co-culture, NK/AML cells were
assayed for IDO1 expression by western blotting. As shown
in Figure 1A, co-culture of NK cells with AML blasts re-
sulted positive for IDO1 expression when compared withl. This is an Open Access article distributed under the terms of the Creative
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AML co-culture performed in the presence of inhibitory
anti-Gal-9 antibody (Ab) revealed a strong down-regulation
of IDO1 induction. The activity of IDO1 in the different
culture conditions was validated by kynurenine production
resulting from its enzymatic activity. We also quantified
IFNγ production in the supernatants of co-cultures by
ELISA assay. As shown in Figure 1B, NK/AML co-culture
induces a fivefold increase in IFNγ production compared to
culture of NK cells alone. The addition of anti-Gal-9 Ab to
cultures resulted in a significant reduction of IFNγ pro-
duced by NK cells. To monitor the effect of IFNγ produc-
tion, we evaluated the level of interferon regulatory factor 1
(IRF1), a transcription activator of genes induced by inter-
feron. As shown in Figure 1A, IRF1 shows the same trend
of expression of IDO1 and correlates with the amount of
IFNγ produced. To emphasize that IDO1 expression in
AML blasts depends on NK cell-mediated IFNγ produc-
tion, we directly stimulated non-IDO1-expressing AML
blasts with the supernatant (SVN) obtained from co-
cultured NK/AML. As shown in Figure 2A, the SVN
derived from the co-culture is able to induce a strong ex-
pression of both IDO1 and IRF1 that correlated with the
increased enzymatic activity. IDO1 induction was almost
comparable with that obtained after addition to culture of
recombinant human IFNγ (100 ng/ml). Expression of
IDO1 and IRF1 strongly correlated with the level of IFNγ
production in all the three culture conditions (Figure 2B).
Consistent with previous data [11], we showed thatFigure 1 NK/AML co-culture induces TIM-3/Gal-9-dependent IDO-1 activat
Ficoll-Paque Plus to obtain BM mononuclear cells. PBMC cells processed from
feeder layer of irradiated RPMI 8866 cells to obtain polyclonal expansion of NK
(5:1 ratio) of AML blasts and AML blasts pre-treated for 1 h with anti-Gal-9 ant
as loading control. Supernatants were collected and used for the measureme
Results shown are representative of 3 AML samples. (B) ELISA assay for IFNγ r
Bars are representative of mean values and standard deviation recorded in thIDO1+-AML blasts are able to strongly down-regulate
NK-cell degranulation compared to unstimulated AML
blasts (Additional file 1: Figure S2). These results demon-
strate that in the microenvironment of AML, the dysfunc-
tional effect exerted on NK cells could be due to the
AML-IDO1 induced by NK/AML interaction. In particu-
lar, IFNγ production mediated by TIM-3/Gal-9 interaction
and the consequent IDO1 expression induced in AML
blasts could affect NK cell degranulation activity favoring
AML immune escape. Furthermore, the ability of anti-
Gal-9 Ab to reduce IFNγ production by blocking TIM-3/
Gal-9 interaction supports the hypothesis that in vivo ad-
ministration of monoclonal antibodies (mAbs) may suc-
cessfully integrate current chemotherapeutic approaches,
increasing their efficacy. Indeed, recently, administration
of mAbs interfering with immune checkpoints, including
TIM-3/Gal-9, shows encouraging clinical results [12]. In
conclusion, our findings could constitute a definitive proof
of the relation, occurring in leukemia microenvironment,
between IDO1 induction on AML blasts mediated by NK
cell-produced IFNγ and the consequent functional de-
regulation of NK cells that favors AML immune escape.
Materials and methods
Sample collection
Bone marrow samples from patients at the onset of
AML were aseptically withdrawn and collected in EDTA-
containing tubes. The samples were used to isolate
BMMC by density gradient centrifugation by Ficoll-Paqueion. BM samples from children with AML at diagnosis were processed by
buffy coat preparations of healthy donors were cultured for 10 days on a
cells. (A) IDO1 and IRF1 expression on protein extracts from 24-h culture
ibody with NK cells compared with NK cells alone. GAPDH Ab was used
nt of kynurenine levels by RP-HPLC in the different culture conditions.
elease was performed in the supernatants of experimental co-cultures.


















































Figure 2 NK/AML co-culture supernatants induce IFNγ-dependent IDO1 activation. Supernatants obtained from AML alone, stimulated overnight
with rh-IFNγ 100 ng/ml and co-cultured with NK cells were used to culture AML blasts that do not spontaneously express IDO1. (A) IDO1 and
IRF1 expression was evaluated by western blotting and compared with kynurenine release in the new culture supernatants. GAPDH Ab was used
as loading control. Results shown in the figure are representative of three AML samples. (B) ELISA assay for IFNγ quantification was performed in
the new three culture conditions. Bars are representative of mean values and standard deviation recorded in three independent experiments
performed in duplicate (*P < 0.05; **P < 0.01).
Folgiero et al. Journal of Hematology & Oncology  (2015) 8:36 Page 3 of 5Plus. The cells were either used fresh or were stored in
FCS with 10% dimethyl sulfoxide in the vapor phase of li-
quid nitrogen until the day of experimental manipulation.
Abs and reagents
PE-conjugated anti-CD56, APC-conjugated anti-CD3,
and FITC-conjugated anti-CD107a were purchased from
BD Biosciences (Mountain View, CA). APC-conjugated
anti-TIM-3 was from R & D System. PE-conjugated
anti-Galectin-9 was from Biolegend. Rabbit anti-human
IDO (H-101) and anti-IRF-1 (C-20) were purchased from
Santa Cruz Biotechnology. Rabbit anti-human GAPDH
(D16H11) antibodies were from Cell signaling (Milan, Italy).
Horseradish peroxidase (HRP)-conjugated anti-Rabbit was
purchased from BioRad (Hercules, CA). Recombinant
Human IFNγ was from R & D Systems (Minneapolis, MN).
NK-dependent IDO-1 induction
PBMC cells obtained from buffy coat preparations of
healthy donors were cultured for 10 days on a feeder layer
of RPMI 8866 cells, irradiated at 3,000 Gy. After the valid-
ation of TIM-3 positivity, NK cells were cultured for 24 h
with AML blasts previously validated for Galectin-9 posi-
tivity. At the end of NK/AML cell co-culture, the super-
natant was in part analyzed to validate IDO-1 activity by
HPLC, in part analyzed to quantify IFNγ production and
in part used to stimulate a new aliquot of AML blasts for
48 h. The cellular compartment was analyzed by WB for
IDO-1 expression. AML cells stimulated or not with IFNγ
100 ng/ml were used as controls.Western blotting
Cell pellets were lysed with RIPA buffer [150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris–HCl (pH = 8), 1 mM PMSF, 1 mM EGTA, 50 mM
NaF, 50 mM Na3VO4, and protease inhibitors (Roche,
Milan, Italy)]. Cell lysates were incubated on ice for
20 min and clarified by centrifugation at 14,000 rpm for
20 min. Cell extracts obtained with RIPA buffer were
boiled for 5 min at 95°C and analyzed by 10% SDS-PAGE.
Samples were transferred onto nitrocellulose membrane
(Bio-Rad, Milan, Italy). Blots were probed with primary
antibodies, washed, and developed with HRP-conjugated
rabbit or mouse secondary antibodies (Bio-Rad), as ap-
propriate. The bands were quantified densitometrically
using the ImageJ software (National Institutes of Health,
Bethesda, MD).
IDO1 activity
Tryptophan and kynurenine levels were measured with
reverse-phase HPLC Agilent Technologies 1200. Briefly,
sample aliquots (200 μL) were diluted with 200 μL po-
tassium phosphate buffer (0.05 mol/L pH 6.0) containing
the internal standard 3-nitro-L-tyrosine (100 μmol/L).
Protein was precipitated with 50 μL of trichloroacetic
acid (2 mol/L). The capped tubes with the precipitate
were immediately vortex-mixed and centrifuged for
10 min at 13,000 g. One hundred fifty microliters of the
supernatants was transferred into microvials and placed
into the autosampling device. The samples were analyzed
using a Protocol C18HPH 150 × 4.6 mm 5 μ column (SGE
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Agilent Technologies equipped with spectrophotometric
and fluorescence detectors. Tryptophan was detected by
a fluorescence detector at an excitation wavelength of
285 nm and an emission wavelength of 365 nm. Kynure-
nine and nitrotyrosine were detected by recording UV
absorbance at a wavelength of 360 nm. The elution solv-
ent was as follows: buffer A: potassium phosphate solution
(0.015 mol/L, pH 6.4) containing 27 mL acetonitrile and
buffer B: acetonitrile. Analyses were carried out at a
flow rate 1 mL/min a temperature of 25°C in 12 min.
The concentration of components was calculated ac-
cording to peak heights and was compared with both
3-nitro-L-tyrosine as internal standard and with refer-
ence curves constructed with L-tryptophan (concentra-
tion 10, 20, 30 μmoli/L) and KYN (10, 20, 30 μmoli/L).
The intra-daily coefficient of variation was 1.20% for
tryptophan and 1.25% for kynurenine. Inter-days coeffi-
cient was 3.5% for tryptophan and 3.8% for kynurenine.
ELISA assay
IFNγ was quantitated using a conventional ELISA assay.
Reagents were purchased from Mabtech, Stockholm,
Sweden, and used as recommended. Briefly, 96-well
plates were coated with the first antibody (1 μg/ml in
PBS, 100 μl/well) for 4–12 h at room temperature. After
washing twice with PBS, the wells were saturated with
PBS/BSA 0.5% for 1 h. After washing, the wells received
100 μl of each sample (either neat or diluted in PBS/
BSA 0.5% Tween20 0.01%). Following incubation for
1 h, the wells were washed three times with PBS-Tween.
The second biotinylated antibody diluted at 1 μg/ml in
PBS/BSA-Tween was added. One hour later, the wells
were washed three times with PBS-Tween and alkaline
phosphatase-conjugated streptavidin was added at 1 μg/ml
in PBS/BSA-Tween. After 1 h, the wells washed three times
and the enzyme substrate PNPP (Sigma Aldrich, St. Louis,
MO) was added at 1 mg/ml in diethanolamine buffer pH 9.
Following a 30–60-min incubation at room temperature,
the plates were scanned at 415 nm. IFNγ concentration in
the samples was determinate using a titration curve with a
cytokine standard by the manufacturer.
CD107a degranulation assay
NK cells were selected (NK isolation Kit) from buffy coat
preparations of consenting blood donors and were proc-
essed following the manufacturer’s protocol. NK cells
were activated with 50 IU/ml IL-2 for 24 h. After wash-
ings with PBS, NK cells were co-cultured for 3 h with
either AML blasts and IFNγ-stimulated AML blasts at
1:1, 1:3, and 1:10 effector-to-target (E:T) ratio. K562
(NK-sensitive) or Raji cells (NK-resistant) were used as
NK activity control, as previously published. Thereafter,
the cells were labeled with PE-conjugated anti-CD56,APC-conjugated anti-CD-3, and FITC-conjugated anti-
CD107a antibodies for 20 min at 4°C, followed by flow cy-
tometry analysis. Isotype-matched antibodies from the same
manufacturer were used to assess background fluorescence.
Additional file
Additional file 1: Figure S1. Characterization of TIM-3 and Gal-9
expression. (A) AML blasts obtained from BM samples of AML children
were analyzed for Gal-9 expression by FACS analysis. (B) NK cells obtained
from healthy donor buffy coats were tested for TIM-3 expression by FACS
analysis. Results shown in the figure are representative of three different
experiments. Figure S2. IDO1-expressing-AML affects NK degranulation
activity. NK cells were cultured with AML blasts and with AML blasts
pre-treated with IFNγ (1:1 ratio). After 3 h, the cells were harvested and
labeled with CD3, CD56, and CD107a antibodies to evaluate NK cells
degranulation activity by FACS analysis. Results shown in the figure are
representative of three different experiments.
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